USA flag logo/image

An Official Website of the United States Government

Hemostatic Agent Development

Award Information

Agency:
Department of Defense
Branch:
Navy
Award ID:
98526
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
N101-085-0667
Solicitation Year:
N/A
Solicitation Topic Code:
NAVY 10-085
Solicitation Number:
N/A
Small Business Information
HEMCON, INC.
HEMCON, INC. 10575 SW CASCADE AVE, STE 130 PORTLAND, OR 97223 4363
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Hemostatic Agent Development
Agency / Branch: DOD / NAVY
Contract: N00014-10-M-0201
Award Amount: $70,000.00
 

Abstract:

We will develop a novel hemostatic, antimicrobial, resorbable, nanofiber dressing utilizing proven hemorrhage control technology in combination with novel advanced technologies. The nanofiber dressing will be prepared using scaleable NanospiderT electrospinning technology. Nanofiber Based Dressing Constructs (NBDCs) can be prepared to have physical and chemical attributes that closely resemble natural biologic matrix forms such as the body's extracellular matrix. Because of these characteristics, NBDCs are readily conformable with complex injuries and provide for rapid delivery of hemostatic and antimicrobial functionality. We will investigate the use of a new absorbable, hemostatic, electrospinnable chitosan derivative. The chitosan derivative resorbs rapidly and meets ISO 10993 requirements for a resorbable implantable material. HemCon has performed allergenic human trials using the original base chitosan and has demonstrated absence of shrimp or other allergic responses in hypersensitive individuals. Chitosan surface area, in conjunction with shear promotes platelet activation of clotting. The very high specific surface area of chitosan in the NBDC provides significant advantages in controlling hemorrhage and addressing contamination. HemCon will partner with Haemostatix Ltd to further enhance hemostatic activity by the conjugation of a fibrinogen binding peptide (GPRP) to the NBDC. Initial studies demonstrate that peptide surface coating will control hemorrhage within one minute.

Principal Investigator:

Simon McCarthy
Global Head, Research
5032450459
simonm@hemcon.com

Business Contact:

Michelle Sells
Strategic Alliance Manage
9712234905
msells@hemcon.com
Small Business Information at Submission:

HemCon Inc
10575 SW Cascade Ave Suite 130 Portland, OR 97223

EIN/Tax ID: 931321343
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No